絞り込み

16644

広告

「"Goetz MP "[Author]」の検索結果

153件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

The emerging role of CDK4/6i in HER2-positive breast cancer.

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer.

Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

Comparison of Tc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction between SLC38A7 and ALPPL2.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.

ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
Sort by
※並べ替えは表示に時間がかかります